Phase II study of CCI779 [temsirolimus] (NSC 683864) in patients with metastatic melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Temsirolimus (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Jun 2015 Biomarkers information updated
- 16 Feb 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 06 Aug 2008 Actual completion date is Sep 2005 as reported by ClinicalTrials.gov.